Clinical trials: Tace
Hepatocellular Carcinoma, Neoplasms
DC-CIK Combined With TACE in the Treatment of Hepatocellular Carcinoma
Evaluation of DC-CIK cells combined TACE treatment for HCC
- Conditions
- Hepatocellular Carcinoma, Neoplasms, Digestive System Neoplasms
- Trial name
- NCT02487017
- Testing
- Transcatheter Arterial Chemoembolization (TACE), DC-CIK
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shenzhen Hornetcorn Bio-technology Company, LTD
Hepatocellular Carcinoma (HCC)
Study in the Treatment of HCC With a Radiopaque (RO) Bead (LC Bead LUMI™) Loaded With Doxorubicin
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. This type of cancer may be "hypervascular". Hypervascular means there is an increased number or concentration of blood vessels.
- Trial name
- NCT03452553
- Testing
- LC Bead LUMI™ (Radiopaque (RO) Bead) loaded with doxorubicin
- Sponsor
- Boston Scientific Corporation
Hepatocellular Carcinoma
Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma
Systemic therapy is the primary option for managing advanced hepatocellular carcinoma (HCC). The combination of atezolizumab and bevacizumab (A+B) has emerged as the first-choice treatment for advanced HCC(IM brave 150).
- Trial name
- NCT06199297
- Testing
- Atezolizumab combined with Bevacizumab, Sintilimab combined with Bevacizumab, Transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Sun Yat-sen University
Type 2 Diabetes
Effect of Pioglitazone on TIMP-3 and TACE in Type 2 Diabetes
Background: Pioglitazone has been shown to have potent anti-inflammatory as well anti-atherosclerotic effects. However, the mechanisms by which pioglitazone exerts these effects are not clear.
- Trial name
- PIO-TACE (NCT01223196)
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Hepatocellular Carcinoma, Transarterial Chemoembolization
Survival According to the Feeding Artery Obliteration by Chemoembolization for Unresectable Hepatocellular Carcinoma
The aim of this study was to evaluate whether survival of patients who underwent TACE with unresectable HCC can benefit from intermediate-levels of embolization.
- Trial name
- NCT01677468
- Testing
- Intermediate embolization, Complete embolization
- Where
- 3 sites in South Korea
- Volunteers
- 250 people
- Sponsor
- Hallym University Medical Center
Hepatocellular Carcinoma
Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial
Although resection provided survival benefit for selected HCC patients with PVTT, the recurrence rate is still high for those patients.
- Trial name
- NCT06031285
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Sun Yat-sen University
Unresectable Hepatocellular Carcinom
Conversion Therapy Using TACE/HAIC With Anti-Angiogenic and Immunotherapy for Initially Unresectable Hepatocellular Carcinoma Achieving Complete Response or Resectability, Followed by Surgery or Continued Systemic Treatment: A Prospective Cohort Study
This is a prospective cohort study designed to evaluate the effectiveness and safety of two post-conversion treatment strategies for patients with initially unresectable hepatocellular carcinoma (uHCC).
- Trial name
- THAI-CONVERT (NCT07206511)
- Volunteers
- 278 people
- Sponsor
- Shanghai Zhongshan Hospital
Carcinoma, Hepatocellular
Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib
This study will collect data of patients who are treated with TACE followed by sorafenib for hepatocellular carcinoma (HCC) or patients without Sorafenib after TACE.
- Trial name
- OPTIMIS (NCT01933945)
- Testing
- TACE (transarterial chemoembolization), Sorafenib (Nexavar, BAY43-9006)
- Where
- 31 sites in Austria, Brazil and 29 more
- Volunteers
- 1,676 people
- Sponsor
- Bayer
Hepatocellular Carcinoma
A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
A study to evaluate cadonilimab (AK104) + lenvatinib in combination with transarterial chemoembolization (TACE) versus TACE in participants with incurable/non-metastatic hepatocellular carcinoma
- Trial name
- NCT06371157
- Testing
- AK104, Lenvatinib, TACE
- Where
- 4 sites in China
- Volunteers
- 469 people
- Sponsor
- Akeso
Hepatocellular Carcinoma (HCC)
Can Quantitative MRI After cTACE Help Predict Survival ?
Transcatheter arterial chemoembolization (TACE) is a widely accepted palliative therapy for the treatment of HCC. Palliative means that it does not cure the disease prolongs your life and improves quality of life.
- Trial name
- NCT02173119
- Testing
- MRI post-TACE
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Medical College of Wisconsin
Hepatocellular Carcinoma Non-resectable
The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma
To investigate the safety and efficacy of deferoxamine (DFO) combined with conventional transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC).
- Trial name
- NCT03652467
- Testing
- Conventional TACE, Deferoxamine and conventional TACE
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Jinan Military General Hospital
Hepatocellular Carcinoma (HCC), TACE
DEB-TACE vs cTACE in HCC After TIPS
This is a Phase 3, open-label, multicenter, randomized controlled clinical trial designed to evaluate the efficacy and safety of Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) compared with Conventional…
- Conditions
- Hepatocellular Carcinoma (HCC), TACE, TIPS, DEB-TACE
- Trial name
- UPGRADE (NCT07322848)
- Testing
- DEB-TACE, cTACE
- Where
- China
- Volunteers
- 206 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Hepatocellular Carcinoma (HCC)
Toripalimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE, HAIC, or TACE-HAIC) for Unresectable Hepatocellular Carcinoma: a Phase 2, Multicenter Randomised Non-comparative Trial
Toripalimab and bevacizumab (T-B) was approve for unresectable hepatocellular carcinoma (uHCC). Transartial therapies, including transarterial chemoembolization (TACE), hepatic artery infusion chemotherapy (HAIC), and TACE-HAIC…
- Trial name
- NCT07380633
- Testing
- TACE-HAIC+T-B, HAIC+T-B, TACE+T-B
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Chemoembolization Using LifePearl Polyethylene Glycol Drug Eluting Microspheres With Doxorubicin in HCC
The aim of this study is to collect data on efficacy and tolerability on a large series of patient of different Italian hospitals in order to support the validation of LifePearl with robust and consistent clinical evidence.
- Trial name
- LIFDOX (NCT03734068)
- Testing
- Chemoembolization Using LifePearl, Doxorubicin
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- International Group of Endovascular Oncology
Intrahepatic Cholangiocarcinoma
TACE Plus Tegafur Versus TACE for Intrahepatic Cholangiocarcinoma After Curative Resection
The aim of this study is to compare the outcomes of Transarterial Chemoembolization (TACE) plus Tegafur with TACE alone in patients with intrahepatic cholangiocarcinoma after curative resection
- Trial name
- NCT02588755
- Testing
- TACE+Tegafur, TACE
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma, Hepatocellular Carcinoma by BCLC Stage
Volumetric Analysis of Hepatocellular Carcinoma After Transarterial Chemoembolization
The application of transarterial chemoembolisation (TACE) with drug-eluting beads in patients with hepatocellular carcinoma and its response to the treatment will be observed.
- Trial name
- NCT04780789
- Testing
- Transarterial Chemoembolization
- Volunteers
- 61 people
- Sponsor
- Brno University Hospital
Carcinoma, Hepatocellular
A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).
This study will look at whether our drug (sorafenib) in combination with chemotherapy delivered directly into your tumor using beads (DC Bead) will slow the progression of the disease.
- Trial name
- NCT00855218
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 107 sites in United States, Australia and 11 more
- Volunteers
- 307 people
- Sponsor
- Bayer
Hepatocellular Carcinoma
Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Liver Cancer Receiving Transarterial Chemoembolization With Drug Eluting Beads
This pilot clinical trial compares the use of contrast-enhanced ultrasound to contrast-enhanced magnetic response imaging (MRI), the current clinical standard, in predicting treatment response in patients with liver cancer…
- Trial name
- NCT03045497
- Testing
- Perflutren Lipid Microspheres, Dynamic Contrast-Enhanced Ultrasound Imaging, Contrast-enhanced Magnetic Resonance Imaging
- Volunteers
- 15 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Hepatocellular Carcinoma
TACE Combined With Methylcantharidimide Tablets in the Treatment of Large and Unresectable Hepatocellular Carcinoma
The purpose of this study is to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with methylcantharidimide tablets in the treatment of patients with large and unresectable hepatocellular…
- Trial name
- NCT03996681
- Testing
- methylcantharidimide tablets
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Suzhou Municipal Hospital
Hepatocellular Carcinoma
Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma
The investigators design a phase IIB clinical study to explore the efficacy and safety of Donafenib combined with TACE as adjuvant therapy of patients with hepatocellular carcinoma at a high risk of recurrence after radical…
- Trial name
- NCT05161143
- Testing
- Donafenib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital